Development of a TrkAIII-specific antibody will, therefore, be critical for routine immunohistochemical detection of TrkAIII protein expression in order to identify tumours that express TrkAIII mRNA but not TrkAIII protein, which would not be expected to respond to Trk inhibitory therapy [18]. The gene discussed is NTRK1; the disease is neoplasm.